The National Health Surveillance Agency (Anvisa) held, this Thursday (13), a meeting with the Butantan Institute on the use of the Coronavac vaccine against Covid-19 in children and adolescents aged 3 to 17 years.
According to Anvisa, the evaluation enters the final and next stage of the decision. The technical area report will be voted at an extraordinary meeting of Anvisa’s collegiate board. However, the meeting for the presentation of the final report and the vote is not yet scheduled.
The meeting, held online and closed, was attended by specialists from Anvisa, the Butantan Institute, Chilean researchers, technicians from the Sinovac laboratory, from China, and representatives of the Brazilian Society of Infectious Diseases (SBI), of the Infectology Department of the Brazilian Society of Pediatrics (SBP), the Brazilian Society of Immunology (SBI) and the Brazilian Association of Collective Health (Abrasco).
During the meeting, data from research and studies carried out by the Chilean government during the application of Coronavac to children and adolescents in the country were presented and analyzed. According to Anvisa, the invited experts must issue opinions that will be sent for analysis by the agency’s technicians.
The request for emergency use of Coronavac in children and adolescents is still under analysis by the specialists of the General Management of Medicines at Anvisa.
Reference: CNN Brasil
